<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738280</url>
  </required_header>
  <id_info>
    <org_study_id>1296CESC</org_study_id>
    <nct_id>NCT03738280</nct_id>
  </id_info>
  <brief_title>Non-hypovascular Solid Pancreatic Lesions: Role of EUS</brief_title>
  <acronym>LE-VASC</acronym>
  <official_title>Role of EUS in Differential Diagnosis and Malignancy Prediction of Non-hypovascular Solid Pancreatic Lesions: A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular pattern of solid pancreatic lesions (SPLs) has been investigated by different
      abdominal imaging modalities and by contrast-enhanced endoscopic ultrasonography (CE-EUS).
      Compared with surrounding pancreatic parenchyma three different patterns have been described:
      hypo-, iso-, and hypervascular. The majority of SPLs are hypovascular, and the diagnostic
      relevance of hypoenhanced pattern to predict pancreatic adenocarcinoma (PDAC) is well
      established. Differently, iso- and hypervascular pattern is not specific and can be expressed
      by several SPLs, with different clinical behavior and management. To date, poor is know about
      the role of EUS in differential diagnosis of non-hypovascular SPLs and features associated
      with malignancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Upstream dilation of the main pancreatic duct</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of cases with upstream dilation of main pancreatic duct will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular pattern (iso or hypervascular)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of cases with iso-vascular or hyper-vascular pattern will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion borders (smooth or irregular)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of cases with smooth or irregular borders will be recorded.</description>
  </primary_outcome>
  <enrollment type="Actual">154</enrollment>
  <condition>Solid Pancreatic Neoplasms</condition>
  <condition>Endoscopic Ultrasound</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Endoscopic ultrasound-fine needle biopsy</intervention_name>
    <description>Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients fulfilling inclusion and exclusion criteria will be included in
        the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of one or more solid pancreatic lesions preliminary evaluated by
             contrast-enhanced computed tomography (CE-CT) and/or contrast enhanced magnetic
             resonance imaging (CE-MRI) reporting a non-hypovascular contrast pattern (e.g., iso-
             or hypervascular).

        Exclusion Criteria:

          -  Patients with associated chronic pancreatitis features (e.g., pancreatic
             calcifications)

          -  Lesion with hypovascular pattern at CE-EUS.

          -  Lesion not found or non pancreatic at EUS.

          -  Patients refusing to be included in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stefano Francesco Crinò</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>May 5, 2019</last_update_submitted>
  <last_update_submitted_qc>May 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Integrata Verona</investigator_affiliation>
    <investigator_full_name>Stefano Francesco Crinò, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

